<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520153</url>
  </required_header>
  <id_info>
    <org_study_id>2000022658</org_study_id>
    <nct_id>NCT03520153</nct_id>
  </id_info>
  <brief_title>Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome</brief_title>
  <official_title>Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators' objective is to understand the pathogenesis of diabetes mellitus in
      Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) by: 1) establishing the contributions of
      insulin resistance versus impaired insulin secretion, 2) investigating presence of excess
      glucagon signaling by measuring gluconeogenesis and glycogenolysis, and 3) investigating a
      potential interaction between diabetes and intraductal papillary mucinous neoplasms (IPMNs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific project aims include:

      Aim 1: Determine insulin secretion and sensitivity in subjects with MAS-associated diabetes.

      Aim 2: Measure gluconeogenesis and glycogenolysis in MAS-associated diabetes to investigate a
      potential role for excess glucagon signaling.

      Aim 3: Determine if IPMN development is associated with impairment of insulin secretion prior
      to development of overt diabetes.

      The authors expect that this study will:

        1. Establish the etiology of diabetes in FD/MAS

        2. Increase understanding of the role of IPMNs in pathogenesis of diabetes

        3. Provide critical insights into the pathogenesis of diabetes in FD/MAS
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose tolerance status</measure>
    <time_frame>Baseline</time_frame>
    <description>An oral glucose tolerance test will be performed to assess glucose tolerance status to determine if subjects have pre-IGT, IGT or diabetes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>Baseline</time_frame>
    <description>This primary outcome will be obtained from the oral glucose tolerance test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin secretion</measure>
    <time_frame>Baseline</time_frame>
    <description>This primary outcome will be obtained from the hyperglycemic clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beta cell capacity</measure>
    <time_frame>Baseline</time_frame>
    <description>AIRmax stimulation test during the hyperglycemic clamp to ascertain the maximal acute insulin response (AIR) to arginine, which is a measure of functional beta cell capacity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic glucose fluxes (gluconeogenesis and glycogenolysis)</measure>
    <time_frame>At least 2 weeks post baseline testing</time_frame>
    <description>Measurements from the Hyperinsulinemic Euglycemic Clamp/ 2H20 Study will be used to assess insulin effects on hepatic glucose production and glycerol kinetics isotopes and the deuterium enrichment at carbons 2 and 5 (C2 and C5) of plasma glucose providing information on glucose fluxes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Islet cell antibodies (ICA),</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood draw before the start of oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glutamic acid decarboxylase antibodies (GAD65)</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood draw before the start of oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Islet antigen-2 antibodies (IA-2A)</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood draw before the start of oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zinc transporter 8 (ZnT8)</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood draw before the start of oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting lipid panel</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood draw before the start of oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting incretins</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood draw before the start of oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prandial incretins</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood draw at the end of the oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free fatty acids</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood draw before the start of oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth hormone</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood draw before the start of oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin-like growth factor-1 (IGF-1)</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood draw before the start of oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function (BUN and creatinine)</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood draw before the start of oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood draw before the start of oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis</measure>
    <time_frame>Baseline</time_frame>
    <description>Will be obtained at baseline before the start of oral glucose tolerance test to look for albuminuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycerol</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood draw before the start of oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leptin</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood draw before the start of oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood draw before the start of oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function tests (AST and ALT)</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood draw before the start of oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein (CRP)</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood draw before the start of oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 6 (IL-6)</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood draw before the start of oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis factor alpha (TNF-alpha)</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood draw before the start of oral glucose tolerance test</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Maturity-Onset Diabetes of Young (MODY) genetic testing</measure>
    <time_frame>Baseline</time_frame>
    <description>The test detects deletions in the HNF4A, GCK, HNF1A, HNF1B genes and mutations in the HNF4A, GCK, HNF1A, HNF1B and IPF1. Will be obtained at baseline before the start of oral glucose tolerance test only in those subjects with an existing diagnosis of diabetes mellitus.</description>
  </other_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">28</enrollment>
  <condition>McCune-Albright Syndrome</condition>
  <condition>Fibrous Dysplasia</condition>
  <condition>Intraductal Papillary Mucinous Neoplasm</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>FD/MAS with diabetes mellitus</arm_group_label>
    <description>Fibrous Dysplasia/McCune-Albright Syndrome with diabetes mellitus.
Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FD/MAS without diabetes mellitus</arm_group_label>
    <description>Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus.
Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FD/MAS without diabetes and without IPMN</arm_group_label>
    <description>Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus and without intraductal papillary mucinous neoplasms.
Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FD/MAS without diabetes and with IPMN</arm_group_label>
    <description>Fibrous Dysplasia/McCune-Albright Syndrome without diabetes mellitus and with intraductal papillary mucinous neoplasms.
Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <description>Participants will receive the following interventions: Hyperinsulinemic Euglycemic Clamp and 2H20; Hyperglycemic Clamp; and Oral Glucose Tolerance Test.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperinsulinemic Euglycemic Clamp and 2H20</intervention_name>
    <description>Test is used to assess insulin effects on hepatic glucose production.</description>
    <arm_group_label>FD/MAS with diabetes mellitus</arm_group_label>
    <arm_group_label>FD/MAS without diabetes mellitus</arm_group_label>
    <arm_group_label>FD/MAS without diabetes and without IPMN</arm_group_label>
    <arm_group_label>FD/MAS without diabetes and with IPMN</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperglycemic Clamp</intervention_name>
    <description>Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.</description>
    <arm_group_label>FD/MAS with diabetes mellitus</arm_group_label>
    <arm_group_label>FD/MAS without diabetes mellitus</arm_group_label>
    <arm_group_label>FD/MAS without diabetes and without IPMN</arm_group_label>
    <arm_group_label>FD/MAS without diabetes and with IPMN</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Oral Glucose Tolerance Test</intervention_name>
    <description>The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.</description>
    <arm_group_label>FD/MAS with diabetes mellitus</arm_group_label>
    <arm_group_label>FD/MAS without diabetes mellitus</arm_group_label>
    <arm_group_label>FD/MAS without diabetes and without IPMN</arm_group_label>
    <arm_group_label>FD/MAS without diabetes and with IPMN</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include adult Fibrous dysplasia/McCune-Albright syndrome (FD/MAS)
        subjects (&gt; 18 years-old) with diabetes, without diabetes, with and without intraductal
        papillary mucinous neoplasms (IPMNs). FD/MAS subjects, who are enrolled in the National
        Institutes of Health (NIH) Natural History Study and who have already been screened with an
        MRI of the abdomen or magnetic resonance cholangiopancreatography for pancreatic lesions,
        will be invited to participate in the current study based on an existing diagnosis of
        diabetes and/or IPMNs. In addition, seven adult healthy volunteers will be screened and
        recruited by the investigator from Yale Center for Clinical Investigation (YCCI)
        Recruitment Database.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) group:

          -  Must be diagnosed based on clinical grounds and/or mutation testing on bone and/or
             affected tissue

        Control group:

          -  Must be at least 18 years old

        Exclusion Criteria:

        Fibrous dysplasia/McCune-Albright syndrome (FD/MAS) group:

          -  Unwilling to fully cooperate with the evaluation

          -  Unable to provide informed consent

        Control group:

          -  History of diabetes, insulin resistance, pancreatic disease, pancreatic cysts or
             amylase/lipase abnormality

          -  Use of any type of oral diabetes medications and/or insulin

          -  Unable to provide informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cemre Robinson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cemre Robinson, MD</last_name>
    <phone>(203) 737-3784</phone>
    <email>cemre.robinson@yale.edu</email>
  </overall_contact>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2018</study_first_submitted>
  <study_first_submitted_qc>April 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2018</study_first_posted>
  <last_update_submitted>May 17, 2018</last_update_submitted>
  <last_update_submitted_qc>May 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Fibrous Dysplasia, Polyostotic</mesh_term>
    <mesh_term>Fibrous Dysplasia of Bone</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

